PAHC Stock Up 76.4% in a Year: What's Driving the Rally?
Phibro Animal Health's 76.4% stock surge is fueled by strong sales recovery, global growth and a robust balance sheet.
Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
Dip into a beaten-down market sector for deals on some proven winners.
If You'd Invested $1,000 in Zoetis ( ZTS ) Stock 10 Years Ago, Here's How Much You'd Have Today
The short-term picture has been less rosy than the longer-term one.
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR ( SDZNY Quick QuoteSDZNY - ) and Zoetis ( ZTS Quick QuoteZTS - ) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
Veterinary Diagnostics Market is expected to generate a revenue of USD 4.52 Billion by 2031, Globally, at 6.59% CAGR: Verified Market Research®
Lewes, Delaware, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- The Global Veterinary Diagnostics Market Size is projected to grow at a CAGR of 6.59% from 2024 to 2031, according to a new report published by Verified Market Research®.
2 Stocks to Buy With $5,000 and Hold for a Decade
These two stocks come from completely different industries, but each could boost a long-term investor's returns.
Why Zoetis ( ZTS ) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised
Zoetis posts better-than-expected Q2 results with rising sales of pet medicines, boosting its 2025 outlook.
What's Going On With Zoetis Stock Tuesday? - Zoetis ( NYSE:ZTS )
Zoetis Q2 EPS rose to $1.76 vs. $1.61 estimate; revenue hit $2.50 billion, beating $2.41 billion forecast. Full-year EPS guidance raised to $6.30-$6.40 from $6.20-$6.30. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily. Animal health firm Zoetis Inc.
Zoetis ( ZTS ) Q2 Earnings and Revenues Surpass Estimates
Zoetis (ZTS) delivered earnings and revenue surprises of +8.64% and +2.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
1 Top Dividend Growth Stock to Buy and Hold Forever
The demand for this company's products will continue increasing.
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.
BioCryst Pharmaceuticals ( BCRX ) Surpasses Q2 Earnings and Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of +400.00% and +9.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Market Whales and Their Recent Bets on ZTS Options - Zoetis ( NYSE:ZTS )
Investors with a lot of money to spend have taken a bearish stance on Zoetis ZTS. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.
Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect
ZTS eyes an earnings beat as companion animal drugs like Simparica Trio and Apoquel are expected to drive Q2 revenue gains.
Countdown to Zoetis ( ZTS ) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Zoetis (ZTS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Here's Why Zoetis ( ZTS ) Fell More Than Broader Market
In the latest trading session, Zoetis (ZTS) closed at $148.81, marking a -1.46% move from the previous day.
Aclaris Therapeutics ( ACRS ) Expected to Beat Earnings Estimates: Should You Buy?
Aclaris (ACRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Trump's pharmaceutical tariffs could affect some drugmakers more than others
AbbVie, Bristol Myers Squibb and Eli Lilly appear "relatively well-positioned," while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.
Zoetis ( ZTS ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Do Investors Really Feel About Zoetis? - Zoetis ( NYSE:ZTS )
Zoetis's ZTS short percent of float has fallen 14.56% since its last report. The company recently reported that it has 7.85 million shares sold short, which is 1.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.87 days to cover their ...
Billionaire Terry Smith Sold Fundsmith's Entire Stake in Apple and 11X'd His Position in a Company Whose Addressable Market Can Hit $149 Billion by 2032
The "Warren Buffett of Britain" dumped Buffett's actual No. 1 holding in favor a stock with the legs to run higher.
USNA or ZTS: Which Is the Better Value Stock Right Now?
USNA vs. ZTS: Which Stock Is the Better Value Option?
Zoetis ( ZTS ) Laps the Stock Market: Here's Why
In the most recent trading session, Zoetis (ZTS) closed at $151.19, indicating a +2.59% shift from the previous trading day.
Why Zoetis ( ZTS ) Could Beat Earnings Estimates Again
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Here's Why Zoetis ( ZTS ) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should You Invest in the VanEck Agribusiness ETF ( MOO ) ?
Sector ETF report for MOO ...
Phibro ( PAHC ) Soars 6.8%: Is Further Upside Left in the Stock?
Phibro (PAHC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Phibro's Feed Play Pays Off: JPMorgan Upgrades On Zoetis Deal Boost - Phibro Animal Health ( NASDAQ:PAHC )
JPMorgan upgrades Phibro Animal Health citing strong FY2025 performance and upside potential. Analyst expects healthy FY2026 growth in MFAs, vaccines and nutritional specialties. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
SGIOY or ZTS: Which Is the Better Value Stock Right Now?
SGIOY vs. ZTS: Which Stock Is the Better Value Option?
3 Magnificent S&P 500 Dividend Stocks Down 19% to 26%: Is It Time to Buy the Dip?
I am an adherent to the Gardner-Kretzmann Continuum's strategy of owning at least one stock for each year of your age. Because of this notion, I have 37 "core" holdings that I try to add to consistently over time.However, while the S&P 500 has returned to new highs, three of my core holdings -- a ...
2 Dividend Growth Stocks to Buy and Hold Forever
For investors focused on the long game, there is little reason to sell -- at least, so long as a company generates solid returns through consistently improving financial results, regularly increases its dividend ( if it pays one ) , and maintains strong growth prospects.
Here's Why Zoetis ( ZTS ) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Phibro Animal Health Stock Up 52.8% in a Year: What's Driving the Rise?
PAHC stock is under investors' radar due to its booming animal health sales, new product lines and rising vaccine demand.
Should You Invest in Zoetis ( ZTS ) Based on Bullish Wall Street Views?
The average brokerage recommendation (ABR) for Zoetis (ZTS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Elanco Animal Health Gets Its Bite Back, Pipeline Earns Praise - Elanco Animal Health ( NYSE:ELAN )
Elanco's recent launches could add 5% to overall growth in 2025, per William Blair. EMA panel gives positive opinion on Zenrelia; approval expected by Q3 end. Geopolitical tensions, Fed uncertainty, and fast-moving headlines are driving July volatility.
SGIOY or ZTS: Which Is the Better Value Stock Right Now?
SGIOY vs. ZTS: Which Stock Is the Better Value Option?
Zoetis ( ZTS ) Suffers a Larger Drop Than the General Market: Key Insights
Zoetis (ZTS) closed at $155.06 in the latest trading session, marking a -4.09% move from the prior day.
Oracle To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Wednesday - Darden Restaurants ( NYSE:DRI ) , Centrus Energy ( AMEX:LEU )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Evercore ISI Group raised Centrus Energy Corp. LEU price target from $145 to $205.
$1000 Invested In Zoetis 10 Years Ago Would Be Worth This Much Today - Zoetis ( NYSE:ZTS )
Zoetis ZTS has outperformed the market over the past 10 years by 1.04% on an annualized basis producing an average annual return of 12.01%. Currently, Zoetis has a market capitalization of $69.84 billion.
Zoetis ( ZTS ) Surpasses Market Returns: Some Facts Worth Knowing
Zoetis (ZTS) reached $168.82 at the closing of the latest trading day, reflecting a +1.5% change compared to its last close.
Here's How Much a $1000 Investment in Zoetis Made 10 Years Ago Would Be Worth Today
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
5 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
Steady growth and dividend increases over decades can make investors remarkably wealthy.
Why Is Ironwood ( IRWD ) Down 18.4% Since Last Earnings Report?
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio?
ZTS jumps 13% in a month as strong new product sales, strategic deals, and rising earnings estimates boost investor confidence.
Why Is Zoetis ( ZTS ) Up 8.1% Since Last Earnings Report?
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
2 Recession-Proof Stocks to Buy and Hold
President Trump's trade policies are sparking concerns about a potential recession. Though it's hard to predict an upcoming economic downturn, it's never a bad idea for investors to buy shares of companies that can perform relatively well even in bad times.
DSNKY vs. ZTS: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Drugs stocks have likely encountered both Daiichi Sankyo Co., Ltd. - Sponsored ADR ( DSNKY Quick QuoteDSNKY - ) and Zoetis ( ZTS Quick QuoteZTS - ) . But which of these two companies is the best option for those looking for undervalued stocks?
Animal Feed Additives Market Size Valuation to Reach USD 58.42 Billion by 2031, at CAGR of 5.28% | The Insight Partners
US & Canada, June 02, 2025 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, the animal feed additives market is witnessing significant growth owing to the growing feed production. The report runs an in-depth analysis of market trends, key players, and ...
